Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by demand for the blood-thinner Eliquis and several newer treatments.Adjusted ...

BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

This medication is an anticoagulant ... avoid coadministration with strong dual inhibitors. • Discontinuing eliquis in patients without adequate continuous anticoagulation increases risk ...